The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XTORO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.
Document
Determination of Regulatory Review Period for Purposes of Patent Extension; XTORO
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XTORO and is publishing this notice of that determination as required by law...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
82 FR 41271
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Determination of Regulatory Review Period for Purposes of Patent Extension; XTORO,” thefederalregister.org (August 30, 2017), https://thefederalregister.org/documents/2017-18379/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xtoro.